Elmutaz Mohammed Shaikho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Elmutaz Mohammed Shaikho has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Martin H. Steinberg
Division of Hematology and Medical Oncology Boston University Chobanian & Avedisian School of Medicine Boston Massachusetts USA
7 shared publications - Paola Sebastiani
Institute for Clinical Research and Health Policy Studies, Tufts Medical Center
4 shared publications Abdulrahman Alsultan
Sickle Cell Disease Research Center and Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia
3 shared publicationsDavid H.K. Chui
Department of Medicine, Boston University School of Medicine, 72 E. Concord St, Boston, MA, 02118, USA
3 shared publicationsAmein K. Al-Ali
Al-Omran Scientific Chair, King Faisal University, Al-Ahssa and Institute for Research & Medical Consultation, Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia
2 shared publications- Annalisa Buniello
Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK
2 shared publications
Latest Publications
- Open Access
Systematic disease-agnostic identification of therapeutically actionable targets using the genetics of human plasma proteins
Proteome-wide Mendelian randomization (MR) has emerged as a promising approach in uncovering novel therapeutic targets. However, genetic colocalization analysis has revealed that a third of MR associations lacked a shared causal signal between the protein and disease outcome, raising questions about the effectiveness of this approach. The impact of proteome-wide MR, stratified by cis-trans status, in the presence or absence of genetic colocalization, on therapeutic target identification remains largely unknown. In this study, we conducted genome-wide MR and cis/trans-genetic colocalization analyses using proteomic and complex trait genome-wide association studies. Using two different gold-standard datasets, we found that the enrichment of target-disease pairs supported by MR increased with more p-value stringent thresholds MR p-value, with the evidence of enrichment limited to colocalizing cis-MR associations. Using a phenome-wide proteogenetic colocalization approach, we identified 235 unique targets associated with 168 binary traits at high confidence (at colocalization posterior probability of shared signal > 0.8 and 5% FDR-corrected MR p-value). The majority of the target-trait pairs did not overlap with existing drug targets, highlighting opportunities to investigate novel therapeutic hypotheses. 42% of these non-overlapping target-trait pairs were supported by GWAS, interacting protein partners, animal models, and Mendelian disease evidence. These high confidence target-trait pairs assisted with causal gene identification and helped uncover translationally informative novel biology, especially from trans-colocalizing signals, such as the association of lower intestinal alkaline phosphatase with a higher risk of inflammatory bowel disease in FUT2 non-secretors. Beyond target identification, we used MR of colocalizing signals to infer therapeutic directions and flag potential safety concerns. For example, we found that most genetically predicted therapeutic targets for inflammatory bowel disease could potentially worsen allergic disease phenotypes, except for TNFRSF6B where we observed directionally consistent associations for both phenotypes. Our results are publicly available to download or browse in a web application enabling others to use proteogenomic evidence to appraise therapeutic targets.
Open AccessSystematic disease-agnostic identification of therapeutically actionable targets using the genetics of human plasma proteins
Proteome-wide Mendelian randomization (MR) has emerged as a promising approach in uncovering novel therapeutic targets. However, genetic colocalization analysis has revealed that a third of MR associations lacked a shared causal signal between the protein and disease outcome, raising questions about the effectiveness of this approach. The impact of proteome-wide MR, stratified by cis-trans status, in the presence or absence of genetic colocalization, on therapeutic target identification remains largely unknown. In this study, we conducted genome-wide MR and cis/trans-genetic colocalization analyses using proteomic and complex trait genome-wide association studies. Using two different gold-standard datasets, we found that the enrichment of target-disease pairs supported by MR increased with more p-value stringent thresholds MR p-value, with the evidence of enrichment limited to colocalizing cis-MR associations. Using a phenome-wide proteogenetic colocalization approach, we identified 235 unique targets associated with 168 binary traits at high confidence (at colocalization posterior probability of shared signal > 0.8 and 5% FDR-corrected MR p-value). The majority of the target-trait pairs did not overlap with existing drug targets, highlighting opportunities to investigate novel therapeutic hypotheses. 42% of these non-overlapping target-trait pairs were supported by GWAS, interacting protein partners, animal models, and Mendelian disease evidence. These high confidence target-trait pairs assisted with causal gene identification and helped uncover translationally informative novel biology, especially from trans-colocalizing signals, such as the association of lower intestinal alkaline phosphatase with a higher risk of inflammatory bowel disease in FUT2 non-secretors. Beyond target identification, we used MR of colocalizing signals to infer therapeutic directions and flag potential safety concerns. For example, we found that most genetically predicted therapeutic targets for inflammatory bowel disease could potentially worsen allergic disease phenotypes, except for TNFRSF6B where we observed directionally consistent associations for both phenotypes. Our results are publicly available to download or browse in a web application enabling others to use proteogenomic evidence to appraise therapeutic targets.
- Open Access
A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance
The virus SARS-CoV-2 can exploit biological vulnerabilities in susceptible hosts that predispose to development of severe COVID-19. Previous reports have identified several host proteins related to the interferon response (e.g. OAS1), interleukin-6 signalling (IL-6R), and the coagulation cascade (linked via ABO) that were associated with risk of COVID-19. In the present study, we performed proteome-wide genetic colocalisation tests leveraging publicly available protein and COVID-19 datasets, to identify additional proteins that may contribute to COVID-19 risk. Our analytic approach identified several known targets (e.g. ABO, OAS1), but also nominated new proteins such as soluble FAS (colocalisation probability > 0.9, p = 1 × 10 −4 ), implicating FAS-mediated apoptosis as a potential target for COVID-19 risk. We also undertook polygenic (pan) and cis-Mendelian randomisation analyses that showed consistent associations of genetically predicted ABO protein with several COVID-19 phenotypes. The ABO signal was associated with plasma concentrations of several proteins, with the strongest association observed with CD209 in several proteomic datasets. We demonstrated experimentally that CD209 directly interacts with the spike protein of SARS-CoV-2, suggesting a mechanism that could explain the ABO association with COVID-19. Our work provides a prioritised list of host targets potentially exploited by SARS-CoV-2 and is a precursor for further research on CD209 and FAS as therapeutically tractable targets for COVID-19.
Open AccessA proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance
The virus SARS-CoV-2 can exploit biological vulnerabilities in susceptible hosts that predispose to development of severe COVID-19. Previous reports have identified several host proteins related to the interferon response (e.g. OAS1), interleukin-6 signalling (IL-6R), and the coagulation cascade (linked via ABO) that were associated with risk of COVID-19. In the present study, we performed proteome-wide genetic colocalisation tests leveraging publicly available protein and COVID-19 datasets, to identify additional proteins that may contribute to COVID-19 risk. Our analytic approach identified several known targets (e.g. ABO, OAS1), but also nominated new proteins such as soluble FAS (colocalisation probability > 0.9, p = 1 × 10 −4 ), implicating FAS-mediated apoptosis as a potential target for COVID-19 risk. We also undertook polygenic (pan) and cis-Mendelian randomisation analyses that showed consistent associations of genetically predicted ABO protein with several COVID-19 phenotypes. The ABO signal was associated with plasma concentrations of several proteins, with the strongest association observed with CD209 in several proteomic datasets. We demonstrated experimentally that CD209 directly interacts with the spike protein of SARS-CoV-2, suggesting a mechanism that could explain the ABO association with COVID-19. Our work provides a prioritised list of host targets potentially exploited by SARS-CoV-2 and is a precursor for further research on CD209 and FAS as therapeutically tractable targets for COVID-19.
- Open Access
- 22 October 2019
- Published by American Society of Hematology in Blood Advances
- Vol. 3 (20) , 2995-3001
BCL2L1 is associated with γ-globin gene expression
Key Points: BCL2L1 is associated with HbF gene activation.
- 22 October 2019
- Published by American Society of Hematology in Blood Advances
- Vol. 3 (20) , 2995-3001
Open AccessBCL2L1 is associated with γ-globin gene expression
Key Points: BCL2L1 is associated with HbF gene activation.
- Open Access
- 10 March 2019
- Published by Wiley in British Journal of Haematology
- Vol. 186 (2) , 363-364
Haemolysis in sickle cell anaemia: effects of polymorphisms in α‐globin gene regulatory elements
- 10 March 2019
- Published by Wiley in British Journal of Haematology
- Vol. 186 (2) , 363-364
Open AccessHaemolysis in sickle cell anaemia: effects of polymorphisms in α‐globin gene regulatory elements
- Open Access
- 11 August 2017
- Published by Springer Nature in BMC Genomics
- Vol. 18 (1) , 1-7
A phased SNP-based classification of sickle cell anemia HBB haplotypes
Sickle cell anemia causes severe complications and premature death. Five common β-globin gene cluster haplotypes are each associated with characteristic fetal hemoglobin (HbF) levels. As HbF is the major modulator of disease severity, classifying patients according to haplotype is useful. The first method of haplotype classification used restriction fragment length polymorphisms (RFLPs) to detect single nucleotide polymorphisms (SNPs) in the β-globin gene cluster. This is labor intensive, and error prone. We used genome-wide SNP data imputed to the 1000 Genomes reference panel to obtain phased data distinguishing parental alleles. We successfully haplotyped 813 sickle cell anemia patients previously classified by RFLPs with a concordance >98%. Four SNPs (rs3834466, rs28440105, rs10128556, and rs968857) marking four different restriction enzyme sites unequivocally defined most haplotypes. We were able to assign a haplotype to 86% of samples that were either partially or misclassified using RFLPs. Phased data using only four SNPs allowed unequivocal assignment of a haplotype that was not always possible using a larger number of RFLPs. Given the availability of genome-wide SNP data, our method is rapid and does not require high computational resources.
- 11 August 2017
- Published by Springer Nature in BMC Genomics
- Vol. 18 (1) , 1-7
Open AccessA phased SNP-based classification of sickle cell anemia HBB haplotypes
Sickle cell anemia causes severe complications and premature death. Five common β-globin gene cluster haplotypes are each associated with characteristic fetal hemoglobin (HbF) levels. As HbF is the major modulator of disease severity, classifying patients according to haplotype is useful. The first method of haplotype classification used restriction fragment length polymorphisms (RFLPs) to detect single nucleotide polymorphisms (SNPs) in the β-globin gene cluster. This is labor intensive, and error prone. We used genome-wide SNP data imputed to the 1000 Genomes reference panel to obtain phased data distinguishing parental alleles. We successfully haplotyped 813 sickle cell anemia patients previously classified by RFLPs with a concordance >98%. Four SNPs (rs3834466, rs28440105, rs10128556, and rs968857) marking four different restriction enzyme sites unequivocally defined most haplotypes. We were able to assign a haplotype to 86% of samples that were either partially or misclassified using RFLPs. Phased data using only four SNPs allowed unequivocal assignment of a haplotype that was not always possible using a larger number of RFLPs. Given the availability of genome-wide SNP data, our method is rapid and does not require high computational resources.
- Open Access
- 24 July 2017
- Published by Wiley in American Journal of Hematology
- Vol. 92 (11) , 1233-1242
Fetal hemoglobin in sickle cell anemia: The Arab‐Indian haplotype and new therapeutic agents
Fetal hemoglobin (HbF) has well‐known tempering effects on the symptoms of sickle cell disease and its levels vary among patients with different haplotypes of the sickle hemoglobin gene. Compared with sickle cell anemia haplotypes found in patients of African descent, HbF levels in Saudi and Indian patients with the Arab‐Indian (AI) haplotype exceed that in any other haplotype by nearly twofold. Genetic association studies have identified some loci associated with high HbF in the AI haplotype but these observations require functional confirmation. Saudi patients with the Benin haplotype have HbF levels almost twice as high as African patients with this haplotype but this difference is unexplained. Hydroxyurea is still the only FDA approved drug for HbF induction in sickle cell disease. While most patients treated with hydroxyurea have an increase in HbF and some clinical improvement, 10 to 20% of adults show little response to this agent. We review the genetic basis of HbF regulation focusing on sickle cell anemia in Saudi Arabia and discuss new drugs that can induce increased levels of HbF.
- 24 July 2017
- Published by Wiley in American Journal of Hematology
- Vol. 92 (11) , 1233-1242
Open AccessFetal hemoglobin in sickle cell anemia: The Arab‐Indian haplotype and new therapeutic agents
Fetal hemoglobin (HbF) has well‐known tempering effects on the symptoms of sickle cell disease and its levels vary among patients with different haplotypes of the sickle hemoglobin gene. Compared with sickle cell anemia haplotypes found in patients of African descent, HbF levels in Saudi and Indian patients with the Arab‐Indian (AI) haplotype exceed that in any other haplotype by nearly twofold. Genetic association studies have identified some loci associated with high HbF in the AI haplotype but these observations require functional confirmation. Saudi patients with the Benin haplotype have HbF levels almost twice as high as African patients with this haplotype but this difference is unexplained. Hydroxyurea is still the only FDA approved drug for HbF induction in sickle cell disease. While most patients treated with hydroxyurea have an increase in HbF and some clinical improvement, 10 to 20% of adults show little response to this agent. We review the genetic basis of HbF regulation focusing on sickle cell anemia in Saudi Arabia and discuss new drugs that can induce increased levels of HbF.
- Open Access
- 13 June 2017
- Published by Wiley in American Journal of Hematology
- Vol. 92 (9) , E555-E557
Genetic determinants of HbF in Saudi Arabian and African Benin haplotype sickle cell anemia
- 13 June 2017
- Published by Wiley in American Journal of Hematology
- Vol. 92 (9) , E555-E557
Open AccessGenetic determinants of HbF in Saudi Arabian and African Benin haplotype sickle cell anemia
- Open Access
- 1 April 2017
- Published by Elsevier in Stem Cell Reports
- Vol. 8 (4) , 1076-1085
A Comprehensive, Ethnically Diverse Library of Sickle Cell Disease-Specific Induced Pluripotent Stem Cells
- 1 April 2017
- Published by Elsevier in Stem Cell Reports
- Vol. 8 (4) , 1076-1085
Open AccessA Comprehensive, Ethnically Diverse Library of Sickle Cell Disease-Specific Induced Pluripotent Stem Cells
- 1 July 2016
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 59, 49-51
Variants of ZBTB7A (LRF) and its β-globin gene cluster binding motifs in sickle cell anemia
- 1 July 2016
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 59, 49-51
Variants of ZBTB7A (LRF) and its β-globin gene cluster binding motifs in sickle cell anemia